natgillin/translations-raw huggingface dataset:
Usually, this lesion remains local and can be removed with surgery and people can continue treatment.
Ta kožna sprememba običajno ostane omejena in se jo odstrani s kirurškim posegom, bolnik pa lahko nadaljuje z zdravljenjem.
Usually, treatment is started with Protopic 0.1% ointment twice a day, once in the morning and once in the evening, until the eczema has cleared.
Zdravljenje se ponavadi začne z zdravilom Protopic 0,1% dvakrat na dan, enkrat zjutraj in enkrat zvečer, dokler ekcem ne izgine.
Usually, treatment with enoxaparin sodium is prescribed for 7 to 10 days.
Zdravljenje z natrijevim enoksaparinatom se običajno predpiše za 7 do 10 dni.
uterine bleeding leukorrhe
krvavitve iz maternice, levkoreja
Uterine haemorrhage
Maternična krvavitev
Uterine haemorrhage, uterine atony
maternična krvavitev, atonija maternice
Uterine spasm
krč maternice
Uterovaginal prolapse
Maternično-nožnični prolaps
Uterus
žolčnik
Uterus3
maternica3
uthorised uthorised
egistrácie egistrácie
Utilise an oral syringe to withdraw the prescribed dosage of RAVICTI from the bottle.
Uporabite peroralno brizgo za odvzem predpisanega odmerka zdravila RAVICTI iz steklenice.
Utilising the plunger of the oral syringe, administer RAVICTI into the tube.
Z uporabo bata peroralne brizge aplicirajte zdravilo RAVICTI v sondo.
uveitis (iritis and iridocyclitis)
uveitis (iritis in iridociklitis)
Uveitis is inflammation of the uvea, the middle layer of the eye.
Uveitis je vnetje uvee, srednjega sloja očesa.
uveitis, conjunctival disorder, conjunctival follicles, iris hyperpigmentation.
uveitis, bolezni veznice, konjunktivalni folikli, hiperpigmentacija šarenice
Uveitis, episcleritis, iritis
uveitis, episkleritis, iritis
Uveitis, Iridocyclitis, Lenticular opacities,
uveitis, iridociklitis, motnjave leče, poškodba
uveitis, vision blurred
uveitis, zamegljen vid
uveitisc, vitreous haemorrhage, iritisc, eye oedemad, blepharitisd, reduced visual acuity, foreign body sensation in eyes, conjunctivitis
uveitisc, krvavitve v steklovino, iritisc, očesni edemd, blefaritisd, zmanjšanje ostrine vida, občutek tujka v očesu, konjunktivitis
Uxbridge Business Park Sanderson Road Uxbridge UB8 1DH United Kingdom
Uxbridge Business Park Sanderson Road Uxbridge UB8 1DH Velika Britanija
V1 V2 5 V3
C1 C2
V11I, V32I, L33F, I47V, I50V, I54M, I54L, T74P, L76V, I84V, L89V) and a screening HIV-1 RNA
I47V, I50V, I54M, I54L, T74P, L76V, I84V, L89V) in so imeli plazemsko koncentracijo HIV-1 RNK
V4
5 C3
V5
C5
VA NEPHRON- D was a study in patients with type 2 diabetes mellitus and diabetic nephropathy.
Študija VA NEPHRON-D je zajela bolnike s sladkorno boleznijo tipa 2 in diabetično nefropatijo.
Vaccinate healthy animals only.
Cepimo samo zdrave piščance.
Vaccinate healthy animals only.
Cepite samo zdrave konje.
Vaccinate healthy birds only.
Cepite samo zdrave ptice.
Vaccinate healthy one-day-old chicks only.
Cepite samo zdrave enodnevne piščance.
Vaccinate once from an age of 3 weeks onwards.
Cepite enkrat od starosti 3 tednov dalje.
Vaccinate only fattening rabbits
Cepite samo kunce za pridelavo mesa.
Vaccinate only fattening rabbits.
Cepite samo kunce za pridelavo mesa.
Vaccinate only healthy animals
Cepite samo zdrave živali.
Vaccinate only healthy animals.
Cepite le zdrave živali
Vaccinate only healthy chickens.
Cepite samo zdrave piščance.
Vaccinate only pigs as from 3 weeks of age.
Cepite samo prašiče, starejše od 3 tednov.
Vaccinate pigs by the intramuscular route in the neck.
Cepite prašiče intramuskularno v vrat.
Vaccination
Cepljenja
Vaccination against hepatitis A and B in patients who regularly or repeatedly receive human plasma- derived Factor X products may be warranted.
Pri bolnikih, ki redno ali večkrat prejemajo zdravila s faktorjem X, pridobljenim iz človeške plazme, bo morda potrebno cepljenje proti hepatitisu A in B.
Vaccination course to be completed 6 weeks before treatment
cepljenje, ki ga je treba zaključiti 6 tednov pred zdravljenjem;
Vaccination does not affect the course of FeLV infection in cats already infected with FeLV at the time of vaccination, implying that such cats will excrete FeLV irrespective of vaccination; consequently, these animals will constitute a hazard to susceptible cats in their environment.
Cepljenje nima učinka na razvoj-potek FeLV infekcije pri mačkah, ki so v času cepljenja že okužene s povzročitelji FeLV.
Vaccination during treatment with Tecfidera has not been studied.
Cepljenja med zdravljenjem z zdravilom Tecfidera niso preučili.
Vaccination failure: PT “Vaccination failure”.
Neučinkovitost cepiva: PI „Neučinkovitost zdravila“.
Vaccination in high-risk groups should be considered on an individual basis (see section 4.2).
Za cepljenje v skupinah z velikim tveganjem se je treba odločiti individualno (glejte poglavje 4.2).
Vaccination in high-risk groups should be considered on an individual basis.
O cepljenju pri teh otrocih se odločimo za vsakega posameznika posebej.
Vaccination induces a cell-mediated immunity evidenced by: the appearance of specific IgG2 antibodies to Leishmania infantum excreted secreted proteins,
Dejstvo, da cepljenje inducira celično posredovano imunost dokazuje sledeče: pojavljanje specifičnih IgG2 protiteles proti Leishmania infantumekskrecijsko-sekrecijskim proteinom,
Vaccination is currently not recommended in this age group
Cepljenje v tej starostni skupini trenutno ni priporočeno.
Vaccination is currently not recommended in this age group.
Cepljenje v tej starostni skupini trenutno ni priporočeno.
Vaccination is currently not recommended in this age group.
V tej starostni skupini cepljenje trenutno ni priporočeno.
Vaccination is not a substitute for routine cervical screening.
Cepljenje ni nadomestilo za redne presejalne teste materničnega vratu.
Vaccination is not a substitute for routine cervical screening.
Cepljenje ni zamenjava za presejalne teste raka materničnega vratu.
Vaccination is not currently recommended in this age group.
Cepljenje v tej starostni skupini trenutno ni priporočeno.
Vaccination is recommended where RHDV2 is epidemiologically relevant.
Celjenje se priporoča le tam, kjer je virus RHDV2 epidemiološko relevanten.
Vaccination may be followed by a small local swelling at the injection site (at most 24 cm2) for a short period (at most 14 days).
Po cepljenju se lahko na mestu dajanja pojavi prehodna manjša lokalizirana oteklina (največ 24 cm2), ki hitro izgine (v največ 14 dneh).
Vaccination may be followed by a small local swelling at the injection site (at most 24 cm²) for a short period (at most 14 days).
Po cepljenju se lahko na mestu dajanja pojavi prehodna manjša lokalizirana oteklina (največ 24 cm2), ki hitro izgine (v največ 14 dneh).
Vaccination may be followed by a small local swelling at the injection site, which normally resolves within five weeks.
Po cepljenju se lahko pojavi majhna oteklina na mestu injiciranja, ki navadno izzveni v petih tednih.
Vaccination may cause a slight hyperthermia (less than 1.5°C during a maximum period of 24 hours).
Cepljenje lahko povzroči rahlo povišanje telesne temperature (manj kot 1,5o C v obdobju do največ 24 ur).
Vaccination may cause a slight rise in the animal’s body temperature (less than 1.5°C during a maximum period of 24 hours).
Cepljenje lahko povzroči rahlo povišanje telesne temperature živali (manj kot 1,5 °C v obdobju do največ 24 ur).
Vaccination may exceptionally cause hypersensitivity reactions.
Cepljenje lahko izjemoma povzroči hipersenzitivne reakcije.
Vaccination may exceptionally cause hypersensitivity reactions.
Cepljenje lahko izjemoma povzroči preobčutljivostne reakcije.
Vaccination may result in a transient impairment of growth rate in the immediate period after administration of the vaccine.
Zaradi cepljenja se lahko v obdobju po dajanju cepiva zmanjša rast.
Vaccination of breeding sheep before pregnancy according to the recommended schedule described in section 8 results in reduction of viraemia* and transplacental infection associated with infection by Schmallenberg virus during the first trimester of pregnancy.
Cepljenju plemenskih ovac pred obrejitvijo v skladu s priporočenim programom cepljenja, opisanem v poglavju 4.9, sledi zmanjšanje viremij* in transplacentarnih okužb, ki so posledica okužbe z virusom Schmallenberg v prvem trimesečju brejosti.
Vaccination of cattle, sheep and pigs induced the production of neutralising antibodies that persisted for at least 6 months.
Cepljenje goveda, ovc in prašičev inducira nastanek nevtralizacijskih protiteles, ki vztrajajo vsaj 6 mesecev.
Vaccination of cattle, sheep and pigs induced the production of neutralising antibodies that persisted for at least 6 months.
Cepljenje goveda, ovc in prašičev povzroči nastanek nevtralizirajočih protiteles, ki vztrajajo vsaj 6 mesecev.
Vaccination of gilts (female pigs that have not yet had piglets) and sows (female pigs that have had piglets before) with Suvaxyn Aujeszky 783 + O/W can also result in immunity in the pig’s offspring.
Cepljenje mladic (samic, ki še niso imele pujskov) in svinj (samic, ki so že imele pujske) z zdravilom Suvaxyn Aujeszky 783 + O/W lahko privede tudi do imunosti njihovih potomcev.
Vaccination on two occasions with three to four weeks between injections prevented FeLV from remaining in the blood and prevented the signs of FeLV infection.
Dve cepljenji z razmikom treh do štirih tednov med injekcijama sta preprečili ostajanje FeLV v krvi in preprečili znake okužbe z FeLV.
Vaccination programme
Program cepljenja
Vaccination reminders are sent to the prescribers.
bodo zdravniki, ki predpisujejo zdravilo, prejeli opomnik za cepljenje.
Vaccination schedules for children not vaccinated according to the recommended schedule should be considered on an individual basis.
Shemo cepljenja za otroke, ki niso bili cepljeni po priporočeni shemi, je treba določiti individualno.
Vaccination schedules: IXIARO: Day 0/28, Rabipur: Day 0/7/28.
Urniki cepljenja: IXIARO: Dan 0, 28, Rabipur: Dan 0, 7, 28.
Vaccination scheme
Cepitvena shema
Vaccination should be carried out on MS-free birds at least 4 weeks before expected exposure to virulent MS.
Pri pticah brez M. synoviae je treba cepljenje izvesti vsaj štiri tedne pred pričakovano izpostavljenostjo virulentni M. synoviae.
Vaccination should be postponed for people with a severe illness with fever.
Cepljenje je treba pri osebah z resnejšo boleznijo in povišano telesno temperaturo odložiti.
Vaccination should be postponed in children with a severe infection and high fever.
Cepljenje je treba pri otrocih s hudim vnetjem in zelo povišano telesno temperaturo odložiti.
Vaccination should be postponed in people with recent severe fever.
Cepljenje je treba pri osebah, ki so nedavno imele zelo povišano telesno temperaturo, odložiti.
Vaccination should be preceded by a review of the person’s medical history (in particular previous vaccinations and possible adverse reactions).
Pred cepljenjem je treba preučiti anamnezo (predvsem predhodnih cepljenj in morebitnih neželenih učinkov).
Vaccination was also shown to be safe for use during lactation in ewes and cattle.
Za cepivo je bilo prav tako dokazano, da je varno za uporabo v obdobju laktacije pri ovcah in kravah.
Vaccination with live vaccines (like polio, measles, mumps and rubella) is not recommended, as these vaccines may give you an infection if you have them whilst you are taking Xaluprine.
Cepljenje z živimi cepivi (npr. proti otroški paralizi, ošpicam, mumpsu in rdečkam) ni priporočljivo, saj lahko ta cepiva pri sočasni uporabi z zdravilom Xaluprine povzročajo okužbe.
Vaccination with live vaccines should therefore be given 3 months at the earliest after termination of the entire antileukaemic treatment.
Bolnika lahko zato cepimo z živimi oslabljenimi virusnimi cepivi ne prej kot 3 mesece po zaključku celotnega zdravljenja levkemije.
Vaccination with live virus vaccines is not recommended during treatment and until B cell recovery because of the immunosuppressive effect of obinutuzumab (see section 4.4).
Zaradi imunosupresivnega učinka obinutuzumaba cepljenje z živimi virusnimi cepivi ni priporočljivo med zdravljenjem in do okrevanja celic B (glejte poglavje 4.4).
Vaccination with live virus vaccines is not recommended for at least 2 weeks prior to the start of BLINCYTO treatment, during treatment, and until recovery of B lymphocytes to normal ranges following last treatment cycle.
Cepljenje z živimi virusnimi cepivi ni priporočljivo vsaj 2 tedna pred začetkom zdravljenja z zdravilom BLINCYTO, med zdravljenjem in do normalizacije števila limfocitov B po zadnjem ciklusu zdravljenja.
Vaccination with Nobilis IB 4-91 may induce mild respiratory signs of disease which may persist for a few days depending on the health and condition of the chickens.
Cepljenje z Nobilisom IB 4-91 lahko povzroči blage respiratorne znake bolezni, ki lahko trajajo nekaj dni, odvisno od zdravstvenega in splošnega stanja piščancev.
Vaccination with Nobilis IB 4-91 may induce mild respiratory signs which may persist for a few days depending on the health and condition of the chickens.
Cepljenje z Nobilisom IB 4-91 lahko povzroči blage respiratorne znake bolezni, ki lahko trajajo več dni, odvisno od zdravstvenega in splošnega stanja piščancev.
Vaccinations
Imunizacije
Vaccinations given while taking Tecfidera may be less effective than normal.
Cepljenje med uporabo zdravila Tecfidera je lahko manj učinkovito kot običajno.
Vaccinations with other live organism vaccines are not recommended in immunocompromised individuals (see section 4.4).
Cepljenja z drugimi živimi cepivi pri osebah z oslabljenim imunskim sistemom niso priporočljiva (glejte poglavje 4.4).
Vaccinations/therapeutic infectious agents
Cepljenja/povzročitelji okužb v terapevtske namene
Vaccinations: if possible children should be up to date with all vaccinations before using Humira.
Cepljenja: če je mogoče, naj vaš otrok pred začetkom uporabe zdravila Humira opravi vsa potrebna cepljenja.
Vaccinations: if possible your child should be up to date with all vaccinations before using Humira.
Cepljenja: če je mogoče, naj vaš otrok pred začetkom uporabe zdravila Humira opravi vsa potrebna cepljenja.
Vaccinations: If possible, children should be up to date with all vaccinations before using Enbrel.
Cepljenja: Najbolje je, da otrok pred začetkom zdravljenja z zdravilom Enbrel opravi vsa predvidena cepljenja.
Vaccinations: Some vaccines, such as oral polio vaccine, should not be given during Benepali therapy.
Cepljenja: Med zdravljenjem z zdravilom Benepali nekaterih cepiv, npr. peroralnega cepiva proti otroški paralizi, ni dovoljeno uporabljati.
VACCINE
CEPIVO
Vaccine against Babesia canis.
Cepivo proti Babesii canis
Vaccine against Classical Swine Fever
Cepivo proti klasični prašičji kugi
Vaccine against E. coli and C. perfringens infections
Cepivo proti okužbam z E. coli in C. perfringens
Vaccine against leptospirosis.
Cepivo proti leptospirozi
Vaccine against necrotic enteritis
Cepivo proti nekrotičnemu enteritisu.
Vaccine against progressive atrophic rhinitis.
Cepivo proti progresivnemu atrofičnemu rinitisu
Vaccine against progressive atrophic rhinitis.
Cepivo proti progresivnemu atrofičnemu rinitisu.
Vaccine breakthrough infection (after in utero exposure to
okužba po cepljenju (po in utero izpostavitvi infliksimabu)
Vaccine Dose
Odmerek cepiva
Vaccine efficacies against vaccine-matched influenza viral strains, against all influenza viral strains, and against individual influenza viral subtypes were calculated (Tables 2 and 3).
Izračunali so učinkovitost cepiva proti sevom virusa gripe, ki so se ujemali s cepilnimi sevi, proti vsem sevom virusa gripe in posameznim podtipom virusa gripe (preglednici 2 in 3).
Vaccine efficacy
Učinkovitost cepiva
Vaccine efficacy
Učinkovitost cepiva (95 % IZ)
Vaccine efficacy (%) against rotavirus gastro-enteritis requiring hospitalisation and/or rehydration therapy in a medical facility [95% CI]
Učinkovitost cepiva (%) proti hudemu rotavirusnemu gastroenteritisu, ki je zahteval sprejem v bolnišnico in/ali rehidracijsko zdravljenje v zdravstveni ustanovi [95 % IZ].
Vaccine efficacy (%) against rotavirus gastro-enteritis requiring medical attention
Učinkovitost cepiva (%) proti rotavirusnemu gastroenteritisu, pri katerem je potrebno zdravljenje
Vaccine efficacy (%) against severe rotavirus gastro-enteritis (95% CI)
Učinkovitost cepiva (%) proti hudemu rotavirusnemu gastroenteritisu (95 % IZ)
Vaccine Efficacy = (1 - Relative Risk) x 100 %
Učinkovitost cepiva = (1 - relativno tveganje) x 100
Vaccine Efficacy = (1 - Relative Risk) x 100 %;
Učinkovitost cepiva = (1 - relativno tveganje) x 100 %;
Vaccine efficacy against 6 month persistent infection with HPV-16/18 (relevant surrogate marker for cervical cancer) is summarised in the following table.
Učinkovitost cepiva proti 6-mesečni persistentni okužbi s HPV – 16/18 (relevantni nadomestni marker za raka materničnega vratu) povzema naslednja preglednica.
Vaccine efficacy against 6-month persistent infection was 23.2% (97.7% CI [-23.3; 52.5]) for HPV-31 and 67.7% (97.7% CI [35.9; 84.9]) for HPV-45 in the TVC.
V TVC je bila učinkovitost cepiva proti 6-mesečni persistentni okužbi 23,2 % (97,7 % IZ [-23,3; 52,5]) za HPV-31 in 67,7 % (97,7 % IZ [35,9; 84,9]) za HPV-45.
Vaccine efficacy against 6-month persistent infection was 79.1% (97.7% CI [27.6; 95.9]) for HPV-31 and 76.9% (97.7% CI [18.5; 95.6]) for HPV-45 in the ATP cohort (3 doses of vaccine, DNA negative at months 0 and 6 for the relevant HPV type).
V kohorti PP je bila učinkovitost cepiva proti 6-mesečni persistentni okužbi 79,1 % (97,7 % IZ [27,6; 95,9]) za HPV-31 in 76,9 % (97,7 % IZ [18,5; 95,6]) za HPV-45 (3 odmerki cepiva, DNA-negativnost v mesecu 0 in v mesecu 6 za relevantni HPV tip).
Vaccine efficacy against CIN1+ associated with HPV 16/18 observed in the ATP cohort was 91.7% (96.1% CI: 82.4;96.7).
Učinkovitost cepiva proti CIN 1+, povezanemu s HPV 16/18, ugotovljena v kohorti PP, je bila 91,7 % (96,1 % IZ: 82,4;96,7).
Vaccine efficacy against high grade cervical lesions associated with HPV-16/18 observed in TVC at end of study is presented in Table 3.
Učinkovitost cepiva proti visokostopenjskim spremembam na materničnem vratu, povezanimi s HPV- 16/18, ki je bila ugotovljena v TVC ob koncu študije je prikazana v preglednici 3.
Vaccine efficacy against the primary endpoint CIN2+ at the end of study is presented in Table 1.
Učinkovitost cepiva proti primarnemu opazovanemu dogodku CIN2+ob koncu študije je prikazana v preglednici 1.
Vaccine efficacy against the primary endpoint CIN2+ is presented in Table 1.
Učinkovitost cepiva proti primarnemu opazovanemu dogodku CIN2+ ob koncu študije je prikazana v preglednici 1.
Vaccine efficacy against virological endpoints (6-month and 12-month persistent infection) associated with HPV-16/18 observed in the ATP cohort at the end of study is presented in Table 2.
Učinkovitost cepiva glede na virološka opazovana dogodka (6-mesečna in 12-mesečna persistentna okužba) v zvezi s HPV-16/18, ugotovljena v kohorti PP ob koncu študije je prikazana v preglednici 2.
Vaccine efficacy against virological endpoints (6-month and 12-month persistent infection) associated with HPV-16/18 observed in TVC at end of study is presented in Table 4.
Učinkovitost cepiva proti virološkim opazovanim dogodkom (6 mesečna in 12 mesečna persistentna okužba), povezanimi s HPV-16/18, ugotovljenimi v TVC ob koncu študije je prikazana v preglednici 4.
Vaccine efficacy during the first year of life progressively increased with increasing disease severity, reaching 100% (95% CI: 84.7;100) for Vesikari scores 17.
Med prvim letom življenja se učinkovitost cepiva progresivno povečuje s povečevanjem resnosti bolezni in pri oceni  17 po Vesikariju doseže 100 % (95% interval zaupanja: 84,7;100).
Vaccine efficacy of the acellular pertussis (aP) antigens contained in Hexacima against the most severe WHO-defined typical pertussis ( 21 days of paroxysmal cough) is documented in a randomised double-blind study among infants with a 3 dose primary series using a DTaP vaccine in a highly endemic country (Senegal).
Učinkovitost cepiva z brezceličnimi antigeni oslovskega kašlja (aP), ki jih vsebuje cepivo Hexacima, proti tipičnemu oslovskemu kašlju v skladu z definicijo SZO (napadi kašlja, ki trajajo  21 dni), je dokumentirana v randomizirani dvojno slepi študiji pri dojenčkih z osnovno serijo treh odmerkov s cepivom DTaP v visoko endemični državi (Senegal).
Vaccine efficacy of the acellular pertussis (aP) antigens contained in Hexyon against the most severe WHO-defined typical pertussis ( 21 days of paroxysmal cough) is documented in a randomised double-blind study among infants with a 3 dose primary series using a DTaP vaccine in a highly endemic country (Senegal).
Učinkovitost cepiva z brezceličnimi antigeni oslovskega kašlja (aP), ki jih vsebuje cepivo Hexyon, proti tipičnemu oslovskemu kašlju v skladu z definicijo SZO (napadi kašlja, ki trajajo  21 dni), je dokumentirana v randomizirani dvojno slepi študiji pri dojenčkih z osnovno serijo treh odmerkov s cepivom DTaP v visoko endemični državi (Senegal).
Vaccine efficacy was 100.0% (95% CI: 67.5; 100.0).
Učinkovitost cepiva je bila 100,0 % (95 % IZ: 67,5; 100,0).
Vaccine efficacy was inferred from the demonstration of immunologic non inferiority (based mainly on comparing proportions with rSBA titres at least 8) to licensed meningococcal vaccines.
O učinkovitosti cepiva so sklepali na podlagi dokaza imunološke neinferiornosti (temelječ na primerjavi razmerij titrov rSBA vsaj 8) v primerjavi z odobrenimi cepivi proti meningokokom.
Vaccine Efficacy*
Učinkovitost cepiva
Vaccine recipients should attempt to avoid, whenever possible, close association with severely immunocompromised individuals (e.g. bone marrow transplant recipients requiring isolation) for 1-2 weeks following vaccination.
Prejemniki cepiva morajo, kjer je to mogoče, preprečiti tesen stik s hudo imunsko oslabljenimi osebami (npr. prejemniki kostnega mozga, ki po presaditvi potrebujejo izolacijo) še 1 – 2 tedna po cepljenju.
Vaccine recipients should be informed that Pandemic influenza vaccine H5N1 MedImmune is an attenuated live virus vaccine and has the potential for transmission to immunocompromised contacts.
Prejemnikom Cepiva proti pandemski gripi H5N1 MedImmune je treba povedati, da je to cepivo z oslabljenim živim virusom, ki se lahko prenese na imunsko oslabele osebe, s katerimi ima prejemnik stik.
Vaccine recipients under treatment with influenza antiviral agents should not receive Pandemic influenza vaccine H5N1 MedImmune until 48 hours after the cessation of influenza antiviral therapy.
Prejemniki cepiva, ki trenutno prejemajo zdravljenje s protivirusnimi zdravili proti gripi, smejo Cepivo proti pandemski gripi H5N1 MedImmune dobiti šele 48 ur po prenehanju protivirusnega zdravljenja proti gripi.
Vaccine Response Rate2
Delež odziva na cepivo2
Vaccine serotype IPD(1)
Serotip IPB v cepivu(1)
Vaccine serotypes: 76%
Serotipi cepiva: 76
Vaccine serotypes: 98%
Serotipi cepiva: 98
Vaccine should not be stored back in -70°C after storage at or below -18°C.
Po shranjevanju pri temperaturi –18 °C ali manj se cepivo ne sme ponovno shraniti pri temperaturi –70 °C .
Vaccine should not be stored back in -70°C after storage at or below -18°C. Once thawed, use within 2 hours.
Po shranjevanju pri temperaturi –18 °C ali manj se cepivo ne sme ponovno shraniti pri temperaturi –70 °C. Po odtajanju uporabite v roku 2 ur.
VACCINE VIAL LABEL
Cepivo
Vaccine vial of 1,000 or 5,000 doses
Viala s cepivom s 1 000 ali 5 000 odmerki
Vaccine vial of 10,000 doses
Viala s cepivom z 10 000 odmerki
Vaccine-induced IgG Geometric Mean Titres (GMT) were well above titres observed in women previously infected but who cleared HPV infection (natural infection).
S cepivom povzročeni geometrijski srednji titri IgG so bili znatno večji od titrov pri predhodno okuženih ženskah, pri katerih je okužba s HPV izzvenela (naravna okužba).